Watson Faces Suits Over Trilipix, Rapamune ANDAs

Law360, New York (April 30, 2010, 3:27 PM EDT) -- Watson Pharmaceuticals Inc. has been hit with two patent infringement suits over abbreviated new drug applications to introduce generic versions of Abbott Laboratories cholesterol treatment Trilipix and Pfizer Inc. organ rejection drug Rapamune.

Abbott and Pfizer filed separate complaints against Watson in the U.S. District Court for the Southern District of Florida on Thursday.

Abbott holds U.S. Patent Number 7,259,186 for Trilipix, titled "Salts of fenofibric acid and pharmaceutical formulations thereof,” according to its complaint.

The novel salts and formulations of fenofibric acid are useful as...
To view the full article, register now.